Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Cullinan Therapeutics在周六发布消息，宣布Zipalertinib至关重要的2b REZILIENT1研究的初步数据。
As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior anti-PD1/L1 therapy, and prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
截至2024年1月12日的数据截止日，共有31名患者入组。患者已接受中位数为三个先前的系统性抗癌疗法，包括先前的铂类化疗、先前的抗PD1 / L1疗法和先前的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）疗法。
At data cut-off, 18 patients were evaluable for response and showed similar anti-tumor activity compared with those post prior chemotherapy in the previously reported Phase 1/2a part of the study.
在数据截至日期时，共有18名患者可用于反应评估，并显示出与前文报道的Phase 1/2a研究中先前化疗后相似的抗肿瘤活性。